Previous adjusted EBITDA guidance was $108.0M-113.0M. Raises FY25 Modern Orals sales view to $100.0-$110.0M from $80.0M-95.0M.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TPB:
- Avis Budget downgraded, Sprouts upgraded: Wall Street’s top analyst calls
- Turning Point Brands initiated with a Hold at Needham
- Turning Point Brands: Promising Growth in Nicotine Pouches and Diverse Revenue Streams, But Current Valuation Justifies Hold Rating
- FRE Nicotine Pouches partners with PBR for ‘Unleash The Beast’